

- SA, Pollock RE, Vauthey JN. Preoperative predictors of survival after resection of small hepatocellular carcinomas. *Ann Surg.* 2002;235(5):722–30. (discussion 730-1).
20. Takenaka K, Yamamoto K, Taketomi A, Itasaka H, Adachi E, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. *Hepatology.* 1995;22(1):20–4.
 21. Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. *Hepatology.* 1996;24(2):307–10.
 22. Ko S, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Kin T, Yagura K, Ohyama T, Nishio K, Ohashi K, Sho M, Yamada T, Nakano H. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. *Ann Surg.* 1996;224(5):591–5.
 23. Yamanaka N, Takada M, Tanaka T, Yamanaka J, Yasui C, Ando T, Maeda S, Matsushita K, Okamoto E. Viral serostatus and coexisting inflammatory activity affect metachronous carcinogenesis after hepatectomy for hepatocellular carcinoma. A further report. *J Gastroenterol.* 2000;35(3):206–13.
 24. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, Endo O, Yoshitsugu M, Watanabe N, Matsuzaki S. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. *Cancer.* 2002;94(6):1787–95.
 25. Arai S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S, Tobe T. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. *Cancer.* 1992;69(4):913–9.
 26. Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J. Hepatic resection for large hepatocellular carcinoma. *Am J Surg.* 2001;181(4):347–53.
 27. Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. *J Am Coll Surg.* 2002;194(5):592–602.
 28. Nagano Y, Tanaka K, Togo S, Matsuo K, Kunisaki C, Sugita M, Morioka D, Miura Y, Kubota T, Endo I, Sekido H, Shimada H. Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm. *World J Surg.* 2005;29(1):66–71.
 29. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transpl.* 2005;11(9):1086–92.
 30. Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. *Surgery.* 2000;127(6):603–8.
 31. Liao KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP. Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. *Cancer.* 2005;104(9):1948–55.
 32. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. *J Clin Oncol.* 2002;20(6):1527–36.
 33. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. *Ann Surg.* 2009;249(1):118–23.

Possibility of Adoptive Immunotherapy With Peripheral Blood-derived CD3⁻CD56⁺ and CD3⁺CD56⁺ Cells for Inducing Antihepatocellular Carcinoma and Antihepatitis C Virus Activity

Marlen Doskali,*† Yuka Tanaka,*† Masahiro Ohira,*† Kohei Ishiyama,*†
Hirotaka Tashiro,*† Kazuaki Chayama,†‡ and Hideki Ohdan*†

Summary: We recently showed that interleukin (IL)-2-stimulated CD56⁺ cells derived from the liver exert vigorous cytotoxicity against hepatocellular carcinoma (HCC) by their binding to the tumor necrosis factor-related apoptosis-inducing ligand expressed on natural killer cells and the corresponding death receptors, and exhibit inhibitory effects on hepatitis C virus (HCV) replication by production of a high level of interferon- γ . These findings prompted us to develop a technique to increase the number of such innate components of cellular immunity from peripheral blood mononuclear cells (PBMCs) so that, they can be easily applied for immunotherapy clinically. We expanded CD3⁻CD56⁺ and CD3⁺CD56⁺ cells ex vivo from PBMCs of human volunteers by using media containing IL-2 and anti-CD3 monoclonal antibody. Among the various culture media used, autoserum supplemented X-VIVO 15 most efficiently supported PBMCs expansion and maintained the viability of the expanded cells (approximately 60-fold expansion after 28-d culture). Cultivation of PBMCs in this medium resulted in the highest proportion of CD3⁻CD56⁺ cells among the propagated lymphocytes (approximately 40% after 28-d culture). An experiment using genomic HCV replicon-containing hepatic cells showed that the CD3⁻CD56⁺ cell-enriched expansion strongly inhibited HCV replication when compared with freshly isolated PBMCs. The additional anti-CD3 monoclonal antibody pulse stimulation induced anti-HCV activity even in the CD3⁺CD56⁺ cells among the propagated PBMCs. Further, cytotoxic assay showed that the expansion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells resulted in vigorous cytotoxicity against HCC. In conclusion, CD56⁺ cells obtained from the PBMCs show anti-HCV activity in addition to anti-HCC activity.

Key Words: adoptive immunity, cytotoxicity, hepatocellular carcinoma, hepatitis C virus, peripheral blood mononuclear cells

(*J Immunother* 2011;34:129–138)

Received for publication June 22, 2010; accepted October 19, 2010.

From the *Department of Surgery; †Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science; and ‡Liver Research Project Center, Hiroshima University, Hiroshima, Japan.

Supported by a Grant-in-Aid for Exploratory Research (19659323) from the Japan Society for the Promotion of Science (JSPS), Research on Hepatitis and BSE from the Japanese Ministry of Health, Labor and Welfare grant and the Uehara Memorial Foundation.

The authors have no conflicts of interest to disclose.

Reprints: Hideki Ohdan, Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan (e-mail: hohtdan@hiroshima-u.ac.jp).

Copyright © 2011 by Lippincott Williams & Wilkins

Liver failure and hepatocellular carcinoma (HCC) because of chronic hepatitis C infection are the most common indications for liver transplantation (LT). The incidence of both the conditions has been projected to increase further. Recurrent hepatitis C virus (HCV) infection of allografts is universal, occurs immediately after LT, and is associated with accelerated progression to liver cirrhosis, graft loss, and death.^{1,2} The infection is thought to reflect suppression of the host-effector immune responses that usually control the HCV replication.^{3,4} Further, this immunosuppressive condition is considered to increase the incidence of HCC recurrence after LT.

We recently proposed a novel strategy of adjuvant immunotherapy for preventing HCC recurrence after LT: in this immunotherapy, transplant recipients are intravenously injected with lymphokine-activated killer (LAK) cells including activated CD3⁻CD56⁺ and CD3⁺CD56⁺ cells derived from the liver allografts. Considering that the immunosuppressive regimen currently used after LT reduces the components of adaptive immunity, but effectively maintains the innate components of cellular immunity,^{5,7} augmentation of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells that are thought to play a pivotal role in innate immunity, may be a promising immunotherapeutic approach.⁸ We confirmed that CD56⁺ cells derived from the liver allografts treated with interleukin (IL)-2 and anti-CD3 monoclonal antibody (mAb) express a significantly high level of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is a critical molecule for tumor cell killing; further, these cells showed high cytotoxicity against HCC, with no such effect on normal cells.⁸ After obtaining approval from the ethical committee of our institute, we successfully applied adoptive immunotherapy with liver lymphocytes treated with IL-2 and anti-CD3 mAb to patients with HCC having liver cirrhosis in a phase I trial.⁹ Although the long-term benefits of this approach with regard to the control of HCC recurrence after LT remain to be elucidated, the trial provided a unique opportunity to study whether the administration of liver lymphocytes treated with IL-2 and anti-CD3 mAb can also induce an anti-HCV response in transplant recipients with HCV infection. During the first month after LT, the HCV ribonucleic acid (RNA) titers in the sera of the patients who underwent immunotherapy were markedly low compared with those in the sera of the patients who did not undergo immunotherapy; however, such anti-HCV responses were transient. This observation prompted us to develop a technique to increase the number of innate components of cellular immunity from peripheral blood mononuclear cells (PBMCs) so that they can be easily applied for immunotherapy in the clinical setting.

In this study, we attempted to establish a procedure for the ex vivo expansion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells obtained from PBMCs of healthy volunteers.

MATERIALS AND METHODS

Isolation and Cell Culture

PBMCs obtained from healthy volunteers were isolated by gradient centrifugation with Separate-L (Muto Pure Chemicals Co. Ltd, Tokyo, Japan), and suspended in either X-VIVO 15 medium (Lonza, Walkersville, Inc., MD) or RPMI 1640 medium (Gibco Brl, Grand Island, NY). X-VIVO 15 was supplemented with a 50 mmol/L HEPES buffer (Gibco Brl) and used with or without the addition of heat-inactivated 5% autoserum. RPMI 1640 was supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sanko Chemical Co. Ltd., Tokyo, Japan), 25 mmol/L HEPES buffer (Gibco Brl), 50 mol/L 2 mercaptoethanol (Katayama Chemical Co., Osaka, Japan), 50 U/mL penicillin, and 50 g/mL streptomycin (Gibco Brl). Human recombinant IL-2 (1000 Japanese reference units/mL; Takeda Pharmaceutical, Tokyo, Japan) and 100 ng/mL of anti-CD3 mAb OKT3 (Janssen-Kyowa Co. Ltd., Tokyo, Japan) were added to all culture media, which were maintained at 37°C in a 5% CO₂ incubator during the indicated period. The medium was replaced every 7 days, and cell concentrations were adjusted to 1 × 10⁶ cells/mL. The cell viability was assessed by using the trypan blue dye exclusion test.

Flow Cytometry

Flow cytometric analyses were carried out by using an FACSCalibur dual-laser cytometer (BD Biosciences, San Jose, CA). The following mAbs were used for surface staining of the lymphocytes: fluorescein isothiocyanate (FITC)-conjugated anti-CD3 mAb (clone HIT3a; BD Biosciences), phycoerythrin (PE)-conjugated anti-CD56 mAb (clone B159; BD Biosciences), and biotinylated anti-TRAIL (biotin-conjugated anti-TRAIL) mAb (clone RIK-2; eBioscience, Inc., San Diego, CA). The biotinylated mAb was visualized by using allophycocyanin (APC)-streptavidin (BD Biosciences, San Diego, CA). Dead cells identified by light scattering and propidium iodide staining were excluded from the analysis.

Interferon (IFN)- γ production in the lymphocytes was measured by a combination of cell surface and cytoplasmic mAb staining according to the manufacturer instruction. In brief, 4 hours after treatment with leukocyte activation cocktail (BD GolgiPlug, BD Biosciences), the lymphocytes were stained with surface markers anti-CD3-FITC and anti-CD56-APC (BD Biosciences). After washing, the cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosciences), and washed with 10% Perm/Wash Buffer (BD Biosciences). Subsequently, aliquots were stained with either a mAb against intracellular cytokine anti-IFN- γ -PE or isotype-matched control (BD Biosciences).

Cytotoxicity Assay

HepG2 cells, a hepatoma cell line, were purchased from the Japanese Cancer Research Resources Bank and maintained in 10% RPMI.¹⁰ The cells were labeled with 100 μ Ci Na₂ (⁵¹Cr) O₄ for 60 minutes at 37°C in 5% CO₂ in Dulbecco modified eagle medium (DMEM; Gibco Brl) supplemented with 10% FBS, and then subjected to a cytotoxic assay. The labeled HepG2 cells were adjusted to 1 × 10⁴ cells in 100 μ L volumes and were incubated for 4 hours in a total volume of 200 μ L with effector cells in

10% DMEM in U-bottomed 96-well tissue culture plates (Falcon; Becton Dickinson, Franklin Lakes, NJ). PBMCs from healthy volunteers were used as effectors at effector-target (E:T) ratios of 5:1 to 40:1. As a control, the target cells were incubated in either culture medium alone, to determine spontaneous release, or a mixture of 2% Nonidet P-40 (Nacalai Tesque, Inc., Kyoto, Japan), to define the maximum ⁵¹Cr release. The plates were centrifuged at 1000 rpm for 3 minutes to pack the cell layer at the end of the reaction, after which the cell-free supernatants were carefully harvested and their radioactivity was measured with a gamma counter. The percentage of specific ⁵¹Cr release was calculated by the following formula:

% cytotoxicity =

$$\frac{[(\text{cpm of experimental release} - \text{cpm of spontaneous release})]}{[(\text{cpm of maximum release} - \text{cpm of spontaneous release})]} \times 100.$$

The spontaneous release was < 20% of the maximum release. When indicated, the cytotoxic assay was performed in the presence of 10 μ g/mL of anti-TRAIL mAb (N2B2) or, 10 μ g/mL of anti-Fas ligand (FasL) mAb (MFL3) (both from BD Biosciences), or 50 nmol/L of Concanamycin A (Wako Pure Chemicals, Osaka, Japan), which inhibited perforin-mediated cytotoxicity. All the assays were performed in triplicate.

Coculture With HCV Replicon Cells

The Huh7/Rep-Feo cell line (HCV replicon cells) was kindly gifted by Dr N. Sakamoto (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan). An HCV subgenomic replicon plasmid, pRep-Feo, was derived from pRep-Neo (originally pHCVBneo-delS).¹¹ pRep-Feo carries a fusion gene comprising firefly luciferase (*Fluc*) and neomycin phosphotransferase, as described elsewhere.^{12,13} After culture in the presence of G418 (Wako Pure Chemical Industries), Huh7/Rep-Feo cell lines stably expressing the replicons were established. For the coculture experiments, transwell tissue culture plates (pore size, 1 μ m; Costar, Cambridge, MA) were used. HCV replicon cells (10⁵ cells) were incubated in the lower compartment with different numbers of lymphocytes in the upper compartment. DMEM supplemented with 10% FBS was used in this assay. The HCV replicon cells in the lower compartments were collected 48 hours after coculture for luciferase assay. When indicated, anti-CD3 mAb pulse (1 μ g/mL) was added 24 hours before harvesting. The luciferase activities were measured with a luminometer (Lumat LB940; Berthold Technologies, Germany) using the Bright-Glo Luciferase Assay System (Promega). When indicated, the assays were performed in the presence of 100 μ g/mL anti-human IFN- γ mAb and 100 μ g/mL isotype-matched control mAb (R&D Systems, Minneapolis, MN). All the assays were performed in duplicate.

ELISA Assay

Supernatants of propagated PBMCs were collected after 28 days of culture with or without additional stimulation by anti-CD3 mAb pulse (1 day before harvest). IFN- γ levels in the cell culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA) using Quantikine kit (R&D systems, Minneapolis, MN), according to the manufacturer instructions. Absorbance was measured at 492 nm using a microplate reader MTP-300 (CORONA Electric, Ibaraki, Japan).

Statistical Analysis

The results were statistically analyzed by using either unpaired or paired Student *t* test or the linear regression analysis when appropriate. *P*-values < 0.05 were considered to be statistically significant.

RESULTS

Ex Vivo Expansion of CD3⁻CD56⁺ and CD3⁺CD56⁺ Cells From PBMCs

Although RPMI 1640 medium supplemented with FBS is widely used to propagate PBMCs in the experimental setting, several studies have shown that X-VIVO 15 medium has been used under serum-free conditions to support the growth of human monocytes, macrophages, lymphocytes, and natural killer (NK) cells.^{14–16} X-VIVO 15 contains pharmaceutical grade human albumin, recombinant human insulin, and pasteurized human transferrin; hence, it seems to be favorable in terms of clinical applicability. We compared the capacity of RPMI 1640 and X-VIVO 15 to support the growth of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells from human PBMCs in the presence of IL-2 and anti-CD3 mAb, which are crucial for the expansion of LAK cells.^{17–21} PBMCs obtained from 10 human volunteers expanded after 28 days of culture by about 22-fold (range, 8–55) in RPMI 1640 containing FBS, 38-fold (range, 10–93) in serum free X-VIVO 15, and 62-fold (range 32–97) in X-VIVO 15 containing autoserum (Fig. 1A). Autoserum supplemented X-VIVO 15 most efficiently supported cell expansion and also maintained the viability of the expanded cells (Figs. 1A, B).

Further, the cultivation in X-VIVO 15 containing 5% autoserum constantly resulted in the highest proportion of CD3⁻CD56⁺ cells among the propagated lymphocytes (Fig. 1C). Hence, X-VIVO 15 containing autoserum was used for the subsequent experiments. After being cultured for 28 days in the presence of IL-2 and anti-CD3 mAb, propagated PBMCs exclusively consisted of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells (Fig. 2). The proportion of those 2 cell fractions in the propagated PBMCs varied among individuals. The average proportion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells was 41.5% (range, 4.6%–97.1%) and 51.1% (range, 0.8%–93.7%), respectively.

Vigorous Cytotoxicity of Propagated PBMCs Against HCC

Cytotoxic assays using freshly isolated and propagated PBMCs as the effectors and the HepG2 cell line as target were performed. As shown in Figure 3, the freshly isolated PBMCs barely mediated potent cytotoxicity against HepG2 cells. Although the ratio of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells highly varied among the propagated PBMCs of each individual after 28 days of culture, all propagated PBMCs uniformly exhibited vigorous cytotoxicity against HCC, regardless of the ratio of these cell types, while those propagated PBMCs showed no cytotoxicity against self-lymphoblasts (data not shown).

Anti-HCC Activity of the Propagated PBMCs By TRAIL

The propagated CD3⁻CD56⁺ and CD3⁺CD56⁺ cells expressed TRAIL on their surface (Fig. 4). To determine the contribution of TRAIL to the anti-HCC activity of the propagated PBMCs, the effect of a neutralizing anti-TRAIL mAb was examined in a cytotoxicity assay using

the propagated PBMCs (cultivated for 28 d) as the effector and HepG2 cells as the target. The cytotoxicity of propagated PBMCs against hepatoma cells was partially inhibited by the anti-TRAIL mAb alone and more profoundly inhibited by the combination of anti-TRAIL and anti-FasL mAbs together with Concanamycin A. However, cytotoxicity was detected even in the presence of all those blockers, suggesting that other unknown effectors, in addition to TRAIL, FasL, and perforin, are also involved in hepatoma cell cytotoxicity induced by propagated PBMCs (Fig. 5). These findings indicated that TRAIL expressed on the propagated PBMCs was involved in anti-HCC activity.

Anti-HCV Activity of the Propagated PBMCs

We next analyzed the anti-HCV activity of the propagated PBMCs. Propagated PBMCs strongly inhibited luciferase reporter activity compared with freshly isolated PBMCs (Fig. 6A). The additional anti-CD3 mAb pulse administered 1 day before culturing with HCV replicon-containing cells increased the anti-HCV activity of propagated PBMCs. To identify the cell type expressing the anti-HCV activity, we analyzed the relationship between anti-HCV activity and the ratio of CD3⁻CD56⁺ cells in propagated PBMCs (Fig. 6B). Notably, propagated PBMCs containing more CD3⁻CD56⁺ cells (and, thus, fewer CD3⁺CD56⁺ cells) showed lower luciferase reporter activity, indicating that the anti-HCV activity of CD3⁻CD56⁺ cells was more vigorous than that of CD3⁺CD56⁺ cells. However, this trend was not observed when anti-CD3 mAb pulse was added to the culture medium 1 day before the anti-HCV assay; rather, all propagated PBMCs strongly inhibited luciferase reporter activity regardless of the CD3⁻CD56⁺/CD3⁺CD56⁺ cell ratio. This indicates that the additional anti-CD3 mAb pulse stimulation increased anti-HCV activity of the CD3⁺CD56⁺ cells to levels exhibited by CD3⁻CD56⁺ cells.

We earlier reported that IFN- γ secreted from liver lymphocytes activated by IL-2 and anti-CD3 mAb is responsible for the anti-HCV activity of these cells.⁹ Propagated PBMCs also actively produced IFN- γ (Fig. 7A), which likely played a pivotal role in the anti-HCV activity of these cells. IFN- γ expression was significantly higher in CD3⁻CD56⁺ cells than in CD3⁺CD56⁺ cells, consistently with the anti-HCV activity levels of these cells (Fig. 7B). Even after being cultured for 28 days in the presence of IL-2 and anti-CD3 mAb, a considerable number of CD3⁺CD56⁺ cells could be detected by Flow Cytometry, indicating that CD3 molecules not coated with anti-CD3 mAb were present on the surface of propagated PBMCs. The additional anti-CD3 mAb pulse stimulation 1 day before coculturing propagated PBMCs with HCV replicon-containing cells significantly promoted IFN- γ secretion from CD3⁺CD56⁺ cells (Fig. 8). In addition, blocking IFN- γ with a mAb abrogated the anti-HCV activity of propagated PBMCs cocultured with HCV replicon-containing cells (Fig. 9). Thus, IFN- γ secreted by propagated PBMCs can inhibit HCV virion production probably by suppressing viral RNA and protein synthesis.

DISCUSSION

LAK cells for immunotherapy are conventionally generated after expansion in the presence of IL-2 for a relatively short culture period. The heterogeneous LAK cell population consists of nonmajor histocompatibility complex-restricted CD3⁻CD56⁺ and CD3⁺CD56⁺ cell




FIGURE 1. A, Comparative study for evaluating the capacity of various medium to propagate PBMCs. PBMCs obtained from healthy volunteers (n = 10) were cultured in X-VIVO 15 supplemented with/without 5% autoserum and RPMI 1640 supplemented with 10% FBS. All cultures were performed in the presence of interleukin-2 (IL-2; 1000 JRU/mL) and anti-CD3 monoclonal antibody (100 ng/mL) during 28 days. B, Viability of the PBMCs propagated in the various media. At 7-day culture, cell viability was assessed by using trypan blue dye exclusion test. The data represent the mean ± SEM (n = 10 individuals). C, Phenotypic characteristics of the PBMCs in various media. The representative flow cytometric profiles of the propagated PBMCs from a certain volunteer are shown. The PBMCs were stained with monoclonal antibodies against CD3 and CD56, and analyzed by flow cytometry on day 0 and during culture (on days 7, 14, 21, and 28). FBS indicates fetal bovine serum; PBMCs, peripheral blood mononuclear cells.

subsets, both of which contribute to the cytolytic property of LAK cells.²² The unique CD3⁺CD56⁺ cells are generally referred to as NK-like T cells, because, similar to NK cells, they do not require prior specific sensitization to induce recognition of target cells. Addition of anti-CD3 mAb at the initiation of culture, prolongation of culture duration, and addition of various stimuli at the end of culture are improved methodologies to culture LAK cells and reportedly result in better expansion over the original described method.²³ Such expanded LAK cells have

clinically shown modest efficacy against metastatic renal cell carcinoma and melanoma.²⁴ In this study, X-VIVO 15 medium containing autoserum efficiently supported expansion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells. The CD3⁺CD56⁺ cells in propagated PBMCs did not express invariant T-cell receptors, but express conventional T-cell receptors- α/β in the preliminary experiments (data not shown), indicating that these cells are different from the invariant natural killer T cells. Further studies are required to define the phenotypic and functional properties of




FIGURE 2. The proportion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells among the propagated PBMCs varied among individuals. A, Representative flow cytometric profiles of the propagated PBMCs from 3 different individuals are shown. The PBMCs were cultured in X-VIVO 15 medium supplemented with 5% autoserum in the presence of interleukin-2 and anti-CD3 monoclonal antibody. The harvested cells were stained with monoclonal antibodies against CD3 and CD56, and analyzed on day 0 and 28. B, The proportion of CD3⁻CD56⁺ and CD3⁺CD56⁺ cells among the propagated PBMCs before (day 0) and after (day 28) culture. The data represent mean ± SEM (n = 15 individuals). PBMCs indicates peripheral blood mononuclear cells.

CD3⁻CD56⁺ and CD3⁺CD56⁺ cells among the propagated PBMCs.

X-VIVO 15 medium is more efficient in proliferation CD56⁺ cells than RPMI medium, particularly CD3⁻CD56⁺ cells. To address the possible mechanism underlying this phenomenon, we analyzed the amino acid and cytokine content of X-VIVO 15 and RPMI mediums. X-VIVO 15 contains higher concentrations of branched chain amino acids (valine, leucine, and isoleucine) than RPMI (data not shown). In addition, X-VIVO 15 contains higher concentrations of intercellular adhesion molecule 1 (ICAM)-1. As CD56⁺ cells express the ICAM-1 ligand lymphocyte function-associated antigen 1 (LFA-1), ICAM-1 and LFA-1 binding might promote NK cell activation.

We recently showed that CD3⁻CD56⁺ and CD3⁺CD56⁺ cells can be extracted from the liver allograft perfusate during transplant surgery, and short culture with IL-2 and anti-CD3 mAb induces the anti-HCV activity and the anti-HCC activity of the NK and NK-like T cells.⁹ Short-

term (3 days) stimulation with IL-2 significantly upregulates the expression of TRAIL on liver NK cells, but this effect is barely observed on NK cells from PBMCs. Molecular cloning of TRAIL-receptors elucidated that TRAIL binds to at least 4 receptors: 2 are death-inducing receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5), containing cytoplasmic death domains and mediate signal apoptosis; the other 2 are death-inhibitory receptors (TRAIL-R3/DcR1 and TRAIL-R4/DcR2), lacking a functional death domain and do not mediate apoptosis. However, all have similar affinities and the latter pair may act as decoys.^{25,26}

NK cells can destroy many solid tissue-derived malignant cells, such as melanoma, breast cancer, lung cancer, gastric cancer, colon cancer, renal cancer, and ovarian cancer cell lines: this process is mediated primarily by death receptor-ligand interactions.²⁷ We have found that normal hepatocytes express TRAIL-DR4 and TRAIL-DR5 together with TRAIL-DcR1 and TRAIL-DcR2, but moderately or poorly differentiated HCCs highly express TRAIL-DR4 and




FIGURE 3. The propagated PBMCs showed vigorous cytotoxicity against hepatoma cells. Cytotoxic activities of freshly isolated PBMCs (day 0) and propagated PBMCs after 28 days culture (day 28) against HepG2 cells (a hepatoma cell line) were analyzed by ⁵¹Cr release assay. The data represent the mean ± SEM of the percentage of target lysis at effector-target (E:T) ratios of 40:1, 20:1, 10:1, and 5:1 (n=5 for the freshly isolated PBMCs and n=10 for the propagated PBMCs). There was statistically significant difference in cytotoxicity against the hepatoma cells between the propagated PBMCs and the freshly isolated PBMCs (P<0.05). The data of each person was determined as average of ⁵¹Cr titer in triplicate wells. PBMCs indicates peripheral blood mononuclear cells.




FIGURE 5. The cytotoxicity of the propagated PBMCs against hepatoma cells was partially inhibited by an anti-TRAIL mAb alone and more profoundly inhibited by the combination of the anti-TRAIL mAb and anti-FasL mAb together with CMA. The propagated PBMCs were used as effector cells in assays of cytotoxicity against HepG2 cells (hepatoma cell line) at effector-target (E:T) ratios of (40:1, 20:1, 10:1, and 5:1) in the presence or absence of anti-TRAIL (N2B2) mAb (10 µg/mL), anti-FasL (MFL3) mAb (10 µg/mL), and/or CMA (50 nmol/L). The results shown are the mean ± SD of values from triplicate samples and are representative of 3 similar experiments. CMA indicates Concanamycin A; FasL, Fas ligand; mAb, monoclonal antibody; PBMCs, peripheral blood mononuclear cells; TRAIL, tumor necrosis factor-related apoptosis inducing ligand.

TRAIL-DR5 but did not express TRAIL-DcR1 and TRAIL-DcR2, indicating a susceptibility to TRAIL-expressing NK cell-mediated activity toward HCC.⁸ We now showed that long-term (28 d) cultivation in the presence of IL-2 and anti-

CD3 mAb significantly upregulated the expression of TRAIL even on CD56⁺ cells derived from PBMCs and induces significant cytotoxicity of LAK cells including the CD56⁺ subsets against HCC (Figs. 3, 4). The contribution of




FIGURE 4. The propagated CD3⁻CD56⁺ and CD3⁺CD56⁺ cells expressed the TRAIL on their surface. The histograms represent the log fluorescence intensities obtained on staining for TRAIL after gating on the CD3⁻CD56⁺ (A) and the CD3⁺CD56⁺ (B) cells among freshly isolated PBMCs (day 0) and propagated PBMCs after 28-day culture (day 28). The dotted lines represent negative control staining with isotype-matched monoclonal antibodies. The numbers indicate the percentages of cells positive for TRAIL expression (mean ± SEM, n=10 individuals). PBMCs indicates peripheral blood mononuclear cells; TRAIL, tumor necrosis factor-related apoptosis inducing ligand.




FIGURE 6. Propagated PBMCs exhibit marked anti-HCV activity. **A**, Propagated PBMCs cultured for 28 days in the presence of interleukin-2 and anti-CD3 mAb were incubated with HCV replicon-containing hepatic cells for 48 hours in transwell tissue culture plates (effector:target ratio = 10:1). One day before coculturing PBMCs with HCV replicon-containing cells, anti-CD3 mAb pulse (1 μg/mL) was added or not added to the culture of propagated PBMCs. Bar graphs indicate luciferase activity of HCV replicon-containing cells in the presence of effectors normalized to luciferase activity in the absence of effectors (% of luciferase activity; 5 individuals were used for freshly isolated PBMCs, and 10 individuals for propagated PBMCs). The difference in anti-HCV effect between the propagated PBMCs and the freshly isolated PBMCs was statistically significant (**P* < 0.05). **B**, Propagated PBMCs containing more CD3⁻CD56⁺ cells showed lower luciferase reporter activity without the anti-CD3 mAb pulse. All of the propagated PBMCs strongly inhibited luciferase reporter activity, regardless of the CD3⁻CD56⁺/CD3⁺CD56⁺ cell ratio after the anti-CD3 mAb pulse. Data were obtained from 10 volunteers. Each symbol indicates data from 1 individual. HCV indicates hepatitis C virus; mAb, monoclonal antibody; PBMCs, peripheral blood mononuclear cells.

TRAIL molecules to the cytotoxicity of NK cells against HCC was proved by the effect of a neutralizing anti-TRAIL mAb (Fig. 5).

In addition to anti-neoplastic effects, adoptive immunotherapy with LAK cells may lead to viral clearance. In fact, a reduction in hepatitis B virus (HBV) load has been described in patients undergoing treatment with LAK cells.²⁸ LAK cells might suppress HBV replication through the secretion of IFN-γ and tumor necrosis factor-α. Despite such an attractive approach, this therapy has never been applied to suppress HCV replication. In general, in the

early phase of viral infection, the first line of host defense may be effective in removing the virus; however, recent reports have indicated that HCV effectively escapes the innate immune system comprising NK and natural killer T cells, resulting in persistent infection.^{29,30} It has been also reported that cross-linking of CD81 on NK cells by the major envelope protein of HCV, HCV-E2, blocks NK cell activation, IFN-γ production, cytotoxic granule release, and proliferation.²⁹ Engagement of CD81 on NK cells blocks tyrosine phosphorylation through a mechanism that is distinct from the negative signaling pathways associated




FIGURE 7. A, IFN- γ production by propagated PBMCs was evaluated on days 0 and 28 by a combination of cell-surface and cytoplasmic mAb staining and subsequent flow cytometry analysis. Histograms represent log fluorescence intensities obtained by staining whole propagated PBMCs for IFN- γ . Dotted lines represent negative control staining with isotype-matched mAb. Numbers indicate the percentage of cells positive for IFN- γ expression (mean \pm SEM, $n = 5$ individuals). B, IFN- γ expression is higher in CD3⁻CD56⁺ cells than in CD3⁺CD56⁺ cells propagated for 28 days in the presence of interleukin-2 and anti-CD3 mAb ($*P < 0.05$). The data were obtained after gating by staining CD3⁻CD56⁺ and CD3⁺CD56⁺ cells for IFN- γ after 28 days of culture. Data represent mean \pm SEM ($n = 5$ individuals). IFN indicates Interferon; mAb, monoclonal antibody; PBMCs, peripheral blood mononuclear cells.

with NK cell inhibitory receptors for major histocompatibility complex class I molecules.³⁰ These findings prove that HCV-E2-mediated inhibition of NK cells is an efficient HCV evasion strategy, which involves targeting the early antiviral activities of NK cells and allowing the virus to establish itself as a chronic infection. We earlier explored whether CD81 cross-linking-induced inhibitory effects occur even in IL-2-stimulated NK cells. CD81 cross-linking by a mAb specific for CD81 inhibited antitumor cytotoxicity and anti-HCV activity mediated by resting NK cells, but this manipulation did not alter both these activities of IL-2-stimulated NK cells.⁹ This indicated that exposure to IL-2 before CD81 cross-linking abrogates subsequent inhibitory signals in NK cells and encourages us to study the possibility of adoptive immunotherapy with LAK cells to inhibit HCV replication. We have recently shown that CD3⁻CD56⁺ and CD3⁺CD56⁺ cells derived from liver

resident lymphocytes show anti-HCV activity after short-term culture with IL-2 and anti-CD3 mAb through the secretion of IFN- γ .⁹ Similarly, long-term cultivation in the presence of IL-2 and anti-CD3 mAb promotes the inhibitory effects of LAK cells from PBMCs on HCV replication. Although the role of NK cells in controlling HCV infection and replication has not been completely elucidated, a recent report has indicated that NK cells are not directly cytolytic towards HCV replicon-containing hepatic cells, but rather release IFN- γ , suppressing HCV RNA expression.³¹ The role of IFN- γ in the expression of NK cell-mediated anti-HCV activity has been supported by the observation that NK cell-conditioned media have higher levels of signal transducer and activator of transcription 1, a nuclear factor essential in IFN- γ -mediated antiviral pathways. It has also been reported that hepatocytes cultured in NK cell-conditioned media express higher levels of IFN- α/β , IFN regulatory factor 3, and IFN




FIGURE 8. IFN- γ concentrations in culture supernatant increased with the addition of an anti-CD3 mAb pulse. PBMCs were propagated for 28 days in X-VIVO 15 medium supplemented with 5% autoserum in the presence of interleukin-2 and anti-CD3 mAb. One day before harvest, anti-CD3 mAb pulse (1 μ g/mL) was added to the culture. IFN- γ was detected by enzyme-linked immunosorbent assay. Each symbol indicates IFN- γ culture supernatant concentration from each volunteer (n=5 individuals). Horizontal line indicates the mean. IFN- γ expression was significantly different between the supernatants of nonstimulated and stimulated cells (* P <0.05). IFN indicates Interferon; mAb, monoclonal antibody.

regulatory factor 7, confirming that NK cells suppress HCV infection of and replication in human hepatocytes via IFN.³² Similar to recent studies, this study showed that propagated PBMCs consisting of CD56⁺ cells vigorously produce IFN- γ , thus suppressing HCV replication (Figs. 7, 8). However, we have confirmed that IFN- α/β production by propagated CD56⁺ cells was undetectable (data not shown).

Regarding preventing replication of other viruses, earlier studies have shown that IFNs are a group of inducible cytokines with a central role in innate antiviral immune responses because they establish an intracellular antiviral state that prevents viral replication.³³ Mice lacking either IFN- γ or its functional receptor are more susceptible to both viral and bacterial infections, indicating that IFN- γ plays an important role in antiviral and antibacterial responses.^{34,35} It is possible that these propagated PBMCs can prevent the replication of other viruses through an IFN- γ -dependent mechanism. Further studies are required to address this possibility.

We have observed earlier that IL-2-stimulated NK cells were negligibly cytotoxic towards allogeneic and autologous lymphoblasts with 1 shared haplotype despite being strongly cytotoxic to HCC cells.⁸ Therefore, we propose immunotherapy with propagated PBMCs of liver allografts derived from healthy donors with 1 shared haplotype or from the recipient




FIGURE 9. Blocking of IFN- γ with mAb in coculture with HCV replicon-containing hepatic cells abrogated the anti-HCV activity of the propagated PBMCs. HCV replicon-containing hepatic cells incubated with the control medium alone served as control. When HCV replicon-containing hepatic cells were incubated with freshly isolated PBMCs in transwell tissue culture plates (effector: target ratio=10:1), the luciferase activities (indicating HCV replication) were not altered. However, when HCV replicon-containing hepatic cells were incubated with the PBMCs propagated with interleukin-2 and anti-CD3 mAb and additional anti-CD3 mAb pulse stimulation, the luciferase activities were significantly reduced. The propagated PBMCs were used as effector cells in assays of cytotoxicity against HCV replicon-containing hepatic cells in the presence or absence of anti-IFN- γ mAb (100 μ g/mL) and isotype-matched control mAb (100 μ g/mL). Blocking of IFN- γ with mAb elucidated the significant role played by IFN- γ in producing the anti-HCV effect. The bar graphs indicate the rate of luciferase activity of HCV replicon cells in the presence of effectors to that in the absence of effectors (% of luciferase activity) in each group. The data represent the mean \pm SEM of 3 similar experiments. HCV indicates hepatitis C virus; IFN, Interferon; mAb, monoclonal antibody; PBMCs, peripheral blood mononuclear cells.

patients themselves, to mount anti-HCC and anti-HCV responses in HCV-infected LT recipients. Living donor LTs are frequently performed between parent and child who share 1 haplotype of major histocompatibility complex. In this study, we confirmed that CD56⁺ cells from healthy donors expand well, indicating that our approach is realistic. However, it remains to be elucidated whether similar cells can be obtained from recipient patients for adoptive immunotherapy.

In conclusion, CD3⁻CD56⁺ and CD3⁺CD56⁺ cells obtained from the PBMCs show anti-HCV activity in addition to anti-HCC activity and would be used for adoptive immunotherapy in clinical setting.

ACKNOWLEDGMENTS

The authors thank Drs Kentaro Ide, Takashi Onoe, Toshimitsu Irei, Hiroyuki Tahara, Yuka Igarashi, Masataka Banshodani, Nabin Basnet, Hirofumi Tazawa, Keiko Kajitani, Michio Imamura, and Nobuhiko Hiraga for their advice and

encouragement, and Yuko Ishida for expert technical assistance, and Dr Naoya Sakamoto for providing Huh7/Rep-Feo cell line.

REFERENCES

- Brown RS. Hepatitis C and liver transplantation. *Nature*. 2005;436:973–978.
- Petrovic LM. Early recurrence of hepatitis C virus infection after liver transplantation. *Liver Transpl*. 2006;12:S32–S37.
- Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. *Hepatology*. 2002;35:680–687.
- Berenguer M. Natural history of recurrent hepatitis C. *Liver Transpl*. 2002;8:S14–S18.
- Hirata M, Kita Y, Saito S, et al. Increase in natural killer cell activity following living-related liver transplantation. *Transpl Int*. 1998;11(suppl 1):S185–S188.
- Harada N, Shimada M, Okano S, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. *J Immunol*. 2004;173:6635–6644.
- Miller JS, Soignier Y, Panoskaltzis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood*. 2005;105:3051–3057.
- Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. *Hepatology*. 2006;43:362–372.
- Ohira M, Ishiyama K, Tanaka Y, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. *J Clin Invest*. 2009;119:3226–3235.
- Kurokohchi K, Carrington M, Mann DL, et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. *Hepatology*. 1996;23:1181–1188.
- Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. *J Virol*. 2001;75:8516–8523.
- Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep*. 2003;4:602–608.
- Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. *J Infect Dis*. 2004;189:1129–1139.
- Strobl H, Riedl E, Scheinecker C, et al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. *J Immunol*. 1996;157:1499–1507.
- Carlens S, Gilljam M, Remberger M, et al. Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. *Exp Hematol*. 2000;28:1137–1146.
- Bohnenkamp HR, Noll T. Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application. *Cyto-technology*. 2003;42:121–131.
- Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. *J Immunol*. 1994;153:1687–1696.
- Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. *Blood*. 1995;86:3493–3499.
- Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. *Hum Immunol*. 2001;62:1092–1098.
- Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet*. 2000;356:802–807.
- Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. *J Immunother*. 2008;31:63–71.
- Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytotoxicity. *J Exp Med*. 1986;164:814–825.
- Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. *J Immunol*. 1987;138:2728–2733.
- Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med*. 1987;316:889–897.
- Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. *Science*. 1997;276:1111–1113.
- Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science*. 1997;277:818–821.
- Vujanovic NL, Nagashima S, Herberman RB, et al. Non-secretory apoptotic killing by human NK cells. *J Immunol*. 1996;157:1117–1126.
- Shi M, Fu J, Shi F, et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. *Clin Immunol*. 2009;132:43–54.
- Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. *J Exp Med*. 2002;195:43–49.
- Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. *J Exp Med*. 2002;195:35–41.
- Li Y, Zhang T, Ho C, et al. Natural killer cells inhibit hepatitis C virus expression. *J Leukoc Biol*. 2004;76:1171–1179.
- Wang SH, Huang CX, Ye L, et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. *J Viral Hepat*. 2008;15:855–864.
- McFadden G, Mohamed MR, Rahman MM, et al. Cytokine determinants of viral tropism. *Nat Rev Immunol*. 2009;9:645–655.
- Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol*. 2004;75:163–189.
- Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. *Curr Top Microbiol Immunol*. 2007;316:97–117.

Splenectomy in Chronic Hepatic Disorders: Portal Vein Thrombosis and Improvement of Liver Function

Yuichiro Ushitora^a Hirotaka Tashiro^a Shoichi Takahashi^b Hironobu Amano^a
Akihiko Oshita^a Tsuyoshi Kobayashi^a Kazuaki Chayama^b Hideki Ohdan^a

Departments of ^aGastroenterological Surgery, and ^bGastroenterology and Hepatology, Hiroshima University Hospital, Hiroshima, Japan

Key Words

Splenectomy · Interferon · Portal vein thrombosis

Abstract

Background: Splenectomy is gaining increasing importance for cirrhotic patients with hypersplenism. However, its safety and efficacy for patients with chronic liver disease remain unclear. **Methods:** We retrospectively examined the medical records of 38 consecutive cirrhotic patients who underwent splenectomy or simultaneous hepatectomy and splenectomy for hepatocellular carcinoma. **Results:** White blood cell and platelet counts significantly increased 3 months after splenectomy. Serum levels of total bilirubin and prothrombin time significantly improved 1 year after splenectomy. Interferon therapy was administered to 25 patients after splenectomy. A sustained viral response was achieved in 8 patients (42%). The total incidence of portal or splenic vein thrombosis (PSVT) detected by postoperative dynamic computed tomography was 13/38 (34.2%). Multivariate analysis revealed preoperative spleen volume (SV) to be the sole independent predictor of postoperative PSVT. Receiver-operator characteristic curve analysis showed that a cut-off SV of 450 ml corresponded to a sensitivity of 85% and a specificity

of 56%. **Conclusions:** Splenectomy improved the liver function and facilitated effective interferon therapy in cirrhotic patients with hypersplenism, although preoperative SV was frequently associated with postoperative PSVT.

Copyright © 2011 S. Karger AG, Basel

Splenectomy has been performed as a part of Hassab's operation or esophageal transection for control of variceal hemorrhage [1]. Moreover, splenectomy evidently decreases portal pressure [2] and reverses hypersplenism [3], and it has been concurrently performed in patients with small-for-size liver grafts in the setting of living donor liver transplantation [4–6]. Splenectomy is gaining increasing importance for cirrhotic patients with hypersplenism. Thrombocytopenia is a common complication of liver cirrhosis; because of this complication, initiation of antiviral treatment with interferon (IFN) becomes difficult in cirrhotic patients. Patients with thrombocytopenia often receive inadequate or incomplete IFN therapy because of exacerbation of thrombocytopenia. Recently, splenectomy has been indicated and performed in cirrhotic patients undergoing treatment for hepatocellular carcinoma (HCC) to improve thrombocytopenia and

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2011 S. Karger AG, Basel
0253-4886/11/0281-0009\$38.00/0

Accessible online at:
www.karger.com/dsu

Hirotaka Tashiro
Department of Gastroenterological Surgery
Hiroshima University Hospital
Hiroshima 734-8551 (Japan)
E-Mail htashiro@hiroshima-u.ac.jp

prior to induction of IFN therapy for patients with hepatitis C (HCV) [7, 8]. However, the safety and efficacy of IFN therapy after splenectomy remain unclear.

Liver function parameters have been reported to improve after splenectomy [3, 9, 10]. Chen et al. [10] reported that bilirubin levels were significantly lower on postoperative day 7 in patients who underwent simultaneous hepatectomy and splenectomy than in those who underwent only hepatectomy. Sugawara et al. [3] reported a significant reduction in the serum bilirubin levels 1 week after splenectomy. However, the long-term effects on liver function parameters after splenectomy remain unclear.

Portal vein thrombosis (PVT), which was considered as an uncommon complication, has been reported to be a possible cause of death after splenectomy [11]. However, with the advancements in diagnostic modalities, the incidence of portal or splenic vein thrombosis (PSVT) may apparently be greater than clinically appreciated, and this condition may be asymptomatic [12–15]. Winslow et al. reported that PSVT occurred in 8 (8%) of 101 patients who underwent splenectomy [12]. Sugawara et al. [3] reported that PVT occurred in 3 (7%) of 48 patients who underwent splenectomy. However, recent studies reported the incidence of PSVT to be between 14 and 55% [16–18]. Ikeda et al. [18] reported that PSVT occurred in 12 (55%) patients who underwent laparoscopic splenectomy. Several risk factors contribute to the onset of PSVT. A large spleen is associated with PSVT development after splenectomy [17, 18]. However, the weight of the spleen cannot be precisely measured because of the loss of blood from the spleen during the operation.

The aim of the current study is to determine the long-term effects of splenectomy on hepatic functions, the efficacy of IFN treatment after splenectomy, and the risk factors, including the volume of the spleen for PSVT.

Patients and Methods

Patients

Between January 2003 and December 2008, 38 consecutive patients underwent splenectomy or simultaneous hepatectomy and splenectomy for HCC at Hiroshima University Hospital. In this study, patients who underwent splenectomy for idiopathic thrombocytopenic purpura or after living donor liver transplantation were excluded. Thirteen patients underwent only open splenectomy, and 2 patients underwent laparoscopic splenectomy. Seven patients underwent Hassab's operation. Sixteen patients underwent simultaneous hepatectomy and splenectomy. Splenectomy was performed by laparotomy or hand-assisted laparoscopic splenectomy (HALS). In open surgery, a midline incision was used, and the vessels at the splenic hilum were ligated and divided at the

tail of the pancreas. For HALS, patients were placed in the right semilateral position, and a 7-cm skin incision for the hand insertion was made in the left subcostal area. The first trocar (12 mm) was inserted on the left of the umbilicus, where the laparoscope was placed. A CO₂ pneumoperitoneum was then created. Three other trocars were inserted under visual control into the epigastric area, the midclavicular line of the subcostal margin, and the left flank. Splenic attachments were divided using electrocautery, or an ultrasonic dissector. The splenic hilar pedicle was transected with an endoscopic linear vascular stapler. In open surgery, an antithrombotic catheter was inserted via the jejunal vein immediately after laparotomy. The top of the catheter was positioned in the recipient portal vein. A transducer was used to measure the portal vein pressure (PVP) during surgery, and the catheter was removed before closing the abdominal operative wound. Computed tomography (CT) was performed preoperatively and at one week, 1 and 6 months after surgery, or when indicated clinically. Spleen volume (SV) was measured from CT images obtained with a workstation (Virtual Place Advance 300, AZE, Ltd.) [19]. The diagnosis of PSVT was made by a radiologist, and PSVT was classified according to the location of the thrombus. When the thrombus was located solely in the splenic vein, the patient was diagnosed with splenic vein thrombosis (SVT). On the other hand, when the thrombus extended into the trunk of the portal vein, the patient was diagnosed with PVT. PVTs were further classified as intrahepatic and extrahepatic thrombosis. Upon the detection of PSVT with the CT scan, we started anticoagulation therapy that consisted of heparin (10,000 U/day, intravenously) followed by warfarin. The dosages of warfarin were adjusted to achieve an international normalized ratio from 1.5 to 2.0. Until PSVT disappearance was confirmed by CT, the administration of warfarin was continued. Antiviral treatment including pegylated IFN α -2b plus ribavirin was started when platelet counts were increased, and no severe surgical complications developed after splenectomy.

Statistical Analysis

Continuous data are shown as mean \pm SEM. The clinical data were compared using the Mann-Whitney U test or Fisher's exact test. The Cox proportional hazards model was used for multivariate analysis. The paired t test was used for comparison of perioperative laboratory data. Receiver-operator characteristic (ROC) curve analysis was performed to determine the optimal cut-off values. Each cut-off value was determined by seeking the most optimal combination of high sensitivity and specificity values, while maintaining the lowest likelihood ratio of a negative test and the highest likelihood ratio of a positive test. p value of less than 0.05 was considered significant. Statistical analysis was performed using the SPSS 16.0 software (SPSS, Chicago, Ill., USA).

Results

Table 1 presents the clinical characteristics of the patients. The patients were 20 men and 18 women (median age, 60.0 years; range, 40–77 years). Thirty-six (94.7%) patients were positive for HCV. The severity of liver disease was evaluated on the basis of the Child-Pugh classification. Of the 38 patients, 27 (71.1%) were classified as Child-




Fig. 1. Changes in white blood cell counts (a), platelet counts (b), the prothrombin time (c), and serum levels of total-bilirubin (d), and albumin (e). Values are expressed as mean \pm SEM. WBC = White blood cells.

Pugh A, and the remaining 11 (28.9%) were classified as Child-Pugh B. Twenty-six (68.4%) patients had previously received IFN therapy, and 19 (50.0%) patients had HCC. Indications for splenectomy included bleeding tendency due to thrombocytopenia ($n = 1$), difficulties in the induction or continuation of IFN therapy due to thrombocytopenia ($n = 31$), difficulties in therapies for HCC due to thrombocytopenia ($n = 2$), endoscopic treatment-resistant esophagogastric varices ($n = 8$). The changes in the laboratory data are shown in figure 1. Hematological tests conducted before and 3 months after the operation revealed a significant increase in the white blood cell count from $3,055 \pm 224$ to $4,821 \pm 252/\mu\text{l}$ ($p < 0.00001$), and in the platelet count, from 54.2 ± 4.3 to $153.5 \pm 13.5 \times 10^3/\mu\text{l}$ ($p < 0.00001$). Moreover, biochemical tests performed before and 1 year after the operation revealed a significant decrease in the serum levels of total bilirubin from 1.10 ± 0.08 to 0.91 ± 0.07 mg/dl ($p = 0.018$), and prothrombin

Table 1. Clinical characteristics of the patients ($n = 38$)

Age, years	60 (40–77)
Male, n	20
Female, n	18
Hepatitis HBV, n	1
Hepatitis HCV, n	36
Hepatitis NBNC, n	1
Child-Pugh A, n	27
Child-Pugh B, n	11
White blood cell count, $/\mu\text{l}$	$3,019 \pm 224$
Hemoglobin, g/dl	12.2 ± 0.29
Platelets, $\times 10^3/\mu\text{l}$	52.4 ± 4.3
Spleen volumetry, ml	493 ± 45.0
Anamnesis of IFN therapy, n	26
Complicating HCC, n	19




Fig. 2. Changes in portal vein pressure. Values are expressed as mean \pm SEM.

Table 2. Comparison of clinical characteristics between patients with or without PSVT after splenectomy

	No PSVT (n = 25)	PSVT (n = 13)	p value
Sex, male/female	16/9	4/9	0.054
HCC, -/+	13/12	6/7	0.73
Preoperative hemoglobin, mg/dl	12.6 \pm 0.38	11.5 \pm 0.32	0.026
Preoperative platelets, 10 ⁴ /mm ³	5.24 \pm 0.37	5.25 \pm 0.95	0.414
Preoperative PT, %	81.7 \pm 2.7	74.0 \pm 2.5	0.031
Antithrombin III	60.0 \pm 3.4	57.5 \pm 4.8	0.410
Child-Pugh, A/B	20/5	7/6	0.096
Splenic volumetry, ml	422 \pm 47.7	621 \pm 82.9	0.011
Operating time, min	263 \pm 15.7	253 \pm 24.2	0.678
Blood loss, ml	508 \pm 62.9	433 \pm 73.8	0.399
Transfusion, -/+	22/3	9/4	0.164

Table 3. Multivariate logistic regression analysis of predictors of PSVT

Variable	p value	OR	95% CI
Sex, female	0.15	3.927	0.609–25.325
Preoperative hemoglobin	0.436	0.773	0.407–1.467
Preoperative PT	0.422	0.96	0.868–1.061
Splenic volumetry	0.036	9.582	1.156–79.415

time (PT) improved significantly from 81 \pm 2.5 to 88.8 \pm 2.2% ($p = 0.015$); however, the serum levels of total albumin did not improve significantly. PVP was significantly decreased from 17.5 \pm 1.33 to 14.4 \pm 1.38 mm Hg immediately after splenectomy ($p = 0.012$) (fig. 2). Of the 38 patients who underwent splenectomy, 25 received IFN plus ribavirin therapy. The median time between the start of IFN plus ribavirin therapy and splenectomy was 48 days (range 13–977 days). In total, a sustained virological response (SVR) was achieved in 8 (42%) of 19 patients who received IFN therapy. At present, 6 patients continue to receive IFN therapy. Owing to depression and severe diarrhea, IFN therapy was discontinued in 3 patients. No patients who underwent splenectomy discontinued IFN therapy due to thrombocytopenia.

The total incidence of PSVT detected by postoperative dynamic CT (asymptomatic or symptomatic) was 13/38 (34.2%). Specifically, 8 patients exhibited SVT, and 5 exhibited PVT. In 11 of these patients, PSVT was detected for 7–10 days after the operation. In 1 patient, PSVT was detected by dynamic CT approximately 6 months after the operation. In addition, it was detected in another patient approximately 3 months after the operation, and total bilirubin levels in this patient temporarily reached 8 mg/dl. Antiplatelet and anticoagulant drugs were successful in all patients, but PSVT recurred in 2 patients. Univariate analysis (table 2) revealed that the preoperative hemoglobin (Hgb) levels and the preoperative PT were significantly lower in patients with PSVT than in those without PSVT. Moreover, the preoperative SV measured by CT volumetry was significantly higher in patients with PSVT than in those without PSVT. However, multivariate analysis (table 3) revealed SV to be the sole predictor of PSVT in patients who had undergone splenectomy ($p = 0.036$). The optimal cut-off value was determined by ROC curve analysis (fig. 3). A cut-off SV of 450 ml corresponded to a sensitivity of 85% and specificity of 56%.

Postoperative complications associated with splenectomy developed in 7 patients; superficial surgical site infection ($n = 3$) and intra-abdominal abscess ($n = 2$) were treated by percutaneous drainage, and ileus ($n = 2$) that occurred about 1 year after splenectomy were treated by open surgery.

Discussion

In our study, platelet counts significantly increased after splenectomy, and this result is consistent with those obtained in other studies [3, 7]. Improvements in the liver

function parameters after splenectomy have been reported in the literature. Shimada et al. [9] showed that the Child-Pugh class and ammonia levels of cirrhotic patients improved after splenectomy. Chen et al. [10] reported a significant decrease in the serum bilirubin levels after splenectomy in hepatectomized patients. Sugawara et al. [3] also reported that serum bilirubin levels significantly decreased after splenectomy. However, these assessments were performed in the range from 7 to 40 days after splenectomy. A few studies have reported the mid-term (less than 6 months) effects of splenectomy. Ikegami et al. [20] reported that in 2 cirrhotic patients, liver function parameters, including total bilirubin, serum albumin levels, and PT, improved 3 months after splenectomy. Morihara et al. [8] reported that total bilirubin levels improved 6 months after splenectomy. However, few studies have reported the long-term (more than 6 months) effects of splenectomy. In our study, the serum level of total bilirubin and PT improved significantly 1 year after splenectomy, although the serum levels of albumin did not significantly improve. These results suggest that splenectomy results in long-term improvement in liver function for more than 6 months after surgery. The hemodynamic status of patients with liver cirrhosis is characterized by a systemic hyperdynamic status. Portal hypertension with hyperdynamic splanchnic inflow increases mesenteric permeability, causing leakage of a large amount of fluid into the abdominal cavity. Splenectomy can decrease the inflow into the portal system, resulting in decreased portal pressure [2, 4]. In the current study, PVP was decreased after splenectomy, and this result is consistent with the previous reports. Although the mechanism by which splenectomy improves the liver function is difficult to explain, the improvement in liver function might be associated with a decrease in PVP after splenectomy. Moreover, splenectomy may modify inflammatory mediator generation. In the endotoxin-induced liver injury model, splenectomy prevented liver injury by suppressing Kupffer cell function and tumor necrosis factor [21]. In the warm ischemia-reperfusion model in rats, splenectomy protected against acute multiple organ damage by inhibiting leukocyte infiltration in livers, release of TNF- α , and expression of caspase-3 [22]. Splenectomy promoted the regeneration and healing of livers in cirrhotic rats via inhibition of the production of TGF- β [23]. Splenectomy may improve the liver function through the modification of hemodynamic status and inflammatory mediators. Furthermore, an SVR was achieved in 8 patients (42%) in this study. The effectiveness of the IFN therapy might indirectly contribute to the improvement in liver function.




Fig. 3. Receiver-operator characteristics curve of SV for predicting postoperative PSVT in 38 patients who underwent splenectomy: * 450 ml; sensitivity, 85%; specificity, 56%.

Initiation of antiviral therapy with IFN is difficult in patients with thrombocytopenia. Patients with low platelet counts often receive inadequate or incomplete IFN therapy because of the necessary dose reduction or the discontinuation of treatment. Splenectomy is known to improve platelet counts in cirrhotic patients with thrombocytopenia. Recently, some studies have reported that IFN therapy can be safely administered to HCV-positive patients with thrombocytopenia after they have undergone splenectomy. Furthermore, these studies showed that none of the patients required a dose reduction or discontinuation of treatment because of thrombocytopenia, and that the treatment outcomes were similar to those for patients without thrombocytopenia [7, 8]. In the current study, an SVR was achieved in 42% of patients with thrombocytopenia, and IFN therapy did not have to be discontinued because of thrombocytopenia in any of the patients.

In the current study, multivariate analysis revealed that an increase in SV is associated with PSVT after splenectomy. ROC curve analysis revealed that an SV greater than 450 ml is associated with PSVT development after splenectomy. Recent reports have shown that the spleen was significantly heavier in patients with PSVT than in those that did not have PSVT; this finding suggests that

the spleen weight is a possible predictor of postoperative PSVT [17, 18]. However, because of blood loss from the spleen during splenectomy, the weight of the resected spleen is not identical to that of the spleen before the operation. This is the first study to show that the SV recorded before splenectomy is associated with PSVT development after splenectomy; in addition, postoperative PSVT can be predicted by performing preoperative CT volumetry of the spleen. In 11 (84%) of 13 patients who developed PSVT, PSVT was detected 7–10 days after the operation. Postoperative dynamic CT should be planned approximately 1 week after splenectomy for early detection of PSVT. Kawanaka et al. [24] reported that preoperative antithrombin (AT)-III activity was the most important predictive factor for PVT, and that treatment

with AT-III concentrates is likely to prevent the development of PSVT. In this study, we have shown that preoperative AT-III activity was not associated with postoperative PSVT. However, as shown in Kawanaka's report, prophylactic administration of AT-III concentrate in the early postoperative phase may prevent postoperative PSVT in case of SV greater than 450 ml, and it might be better to start anticoagulation therapy with a low dose of warfarin 3 or 4 days after the operation, after confirming that postoperative bleeding did not occur.

In conclusion, splenectomy exhibited a long-term positive effect on liver function; furthermore, preoperative SV was associated with postoperative PSVT. IFN therapy did not have to be discontinued because of thrombocytopenia in any of the patients.

References

- Hassab MA: Gastroesophageal decongestion and splenectomy in the treatment of esophageal varices in bilharzial cirrhosis: further studies with a report on 355 operations. *Surg* 1967;61:169–176.
- Shimada M, Iuchi H, Yonemura Y, et al: The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft. *Hepatogastroenterology* 2004;51:625–629.
- Sugawara Y, Yamamoto J, Shimada M, et al: Splenectomy in patients with hepatocellular carcinoma and hypersplenism. *J Am Coll Surg* 2000;190:446–450.
- Sato Y, Yamamoto S, Oya H, et al: Splenectomy for reduction of excessive portal hypertension after adult living-related donor liver transplantation. *Hepatogastroenterology* 2002;49:1652–1655.
- Ikegami T, Shimada M, Imura S, Arakawa Y, Nii A, Morimae Y: Current concept of small-for-size grafts in living donor liver transplantation. *Surg Today* 2008;38:971–982.
- Tashiro H, Itamoto I, Ohdan H, et al: Should splenectomy be performed for hepatitis C patients undergoing living-donor liver transplantation? *J Gastroenterol Hepatol* 2007;22:959–960.
- Hayashi PH, Mehia C, Reimers HJ, Solomon HS, Bacon BR: Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. *J Clin Gastroenterol* 2006;40:740–744.
- Morihara D, Kobayashi M, Ikeda K, et al: Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. *Hepatol Res* 2009;39:439–447.
- Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K: A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism: performing a hepatectomy after a laparoscopic splenectomy. *Surg Endosc* 2000;14:127–130.
- Chen XP, Wu ZD, Huang ZY, Qiu FZ: Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. *Br J Surg* 2005;92:334–339.
- Hanazaki K, Kajikawa S, Adachi W, Amano E: Portal vein thrombosis may be a fatal complication after synchronous splenectomy in patients with hepatocellular carcinoma and hypersplenism. *J Am Coll Surg* 2000;191:341–342.
- Winslow ER, Brunt LM, Drebin JA, Soper NJ, Klingensmith ME: Portal vein thrombosis after splenectomy. *Am J Surg* 2002;184:631–636.
- Rattner DW, Ellman L, Warshaw AL: Portal vein thrombosis after elective splenectomy: an underappreciated, potentially lethal syndrome. *Arch Surg* 1993;128:565–570.
- Chaffanjon PC, Brichon PY, Ranchoup Y, Giressin R, Sotto JJ: Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging. *World J Surg* 1998;22:1082–1086.
- van't Riet M, Burger JW, van Muiswinkel JM, Kazemier G, Schipperus MR, Bonjer HJ: Diagnosis and treatment of portal vein thrombosis following splenectomy. *Br J Surg* 2000;87:1229–1233.
- Romano F, Caprotti R, Scaini A, Conti M, Scotti M, Colombo G: Elective laparoscopic splenectomy and thrombosis of the splenoportal axis: a prospective study with color Doppler ultrasound. *Surg Laparosc Endosc Percutan Tech* 2006;16:4–7.
- Svensson M, Wiren M, Kimby E, Hagglund H: Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases. *Rur J Haematol* 2006;77:203–209.
- Ikeda M, Sekimoto M, Takiguchi S, et al: High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. *Ann Surg* 2005;241:208–216.
- Ohira M, Ishifuro M, Ide K, et al: Significant correlation between spleen volume and liver thrombocytopenia in liver transplant patients: a concept for predicting persistent thrombocytopenia. *Liver Transplant* 2009;15:208–215.
- Ikegami T, Shimada M, Imura S: Recent role of splenectomy in cirrhotic hepatic disorders. *Hepatol Res* 2008;38:1159–1171.
- Suzuki S, Nakamura S, Serizawa A, et al: Role of Kupffer cells and the spleen in modulation of endotoxin-induced liver injury after partial hepatectomy. *Hepatology* 1996;24:219–225.
- liang H, Meng F, Li W, et al: Splenectomy ameliorates acute multiple organ damage induced by liver warm ischemia reperfusion injury in rats. *Surgery* 2007;141:32–40.
- Akahoshi T, Hashizume M, Tanoue K, et al: Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor β . *J Gastroenterol Hepatol* 2002;17:59–65.
- Kawanaka H, Akahoshi T, Kimio N, Konishi K, Yoshida D, Aneawa G, et al: Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. *Ann Surg* 2010;251:76–83.

ORIGINAL ARTICLE

Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus

TOMOKAZU KAWAOKA¹, NOBUHIKO HIRAGA¹, SHOICHI TAKAHASHI¹, SHINTARO TAKAKI¹, FUKIKO MITSUI¹, MASATAKA TSUGE¹, YUKO NAGAOKI¹, YUKI KIMURA¹, YOSHIMASA HASHIMOTO¹, YOSHIO KATAMURA¹, AKIRA HIRAMATSU¹, KOJI WAKI¹, MICHIO IMAMURA¹, YOSHIKU KAWAKAMI¹, HIROSHI AIKATA¹, HIROTAKA TASHIRO², HIDEKI OH DAN² & KAZUAKI CHAYAMA¹

¹Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan, and ²Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan

Abstract

Objective. The aim of the present retrospective study was to evaluate the therapeutic efficacy and predictive factors of prolongation of treatment with peginterferon (PEGIFN) combined with ribavirin (RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT). **Methods.** Fifty-three patients underwent LDLT due to HCV-related end-stage liver disease. Sixteen patients were removed from the study as a result of early death ($n = 14$), no recurrence of HCV ($n = 1$) and refusal of antiviral therapy ($n = 1$). Therapy is ongoing in another 10 patients. The remaining 27 patients were available to establish the efficacy of IFN therapy. HCV genotype was 1b in 24 patients. All patients with genotype 1b were treated with IFN therapy for at least 48 weeks after HCV RNA levels had become undetectable. Amino acid substitutions in the HCV core region and NS5A region were analyzed by direct sequencing before LDLT. **Results.** The rate of sustained virological response (SVR) was 37.0% (10/27). SVR rate in patients with genotype 1 was 29.2% (7/24) and 100% (3/3) in patients with genotype 2. Most patients with genotype 1b whose HCV RNA reached undetectable levels achieved SVR (87.5%; 7/8). However, mutation of the HCV core region and number of ISDR mutations were not associated with SVR rate in LDLT in our study. **Conclusions.** Prolonged IFN therapy for more than 48 weeks after HCV RNA reached undetectable levels might prevent virological relapse of HCV.

Key Words: Core and NS5A regions, HCV, IFN, LDLT

Introduction

Hepatitis C virus (HCV)-related end-stage liver disease is currently the leading indication for liver transplantation (LT). Unfortunately, prevention of HCV infection after transplantation is difficult and, unlike

the situation with the prevention of hepatitis B virus after transplantation [1], HCV re-infection after LT is almost universal, with histological evidence of chronic hepatitis in approximately 50% of patients within 1 year and cirrhosis in about 30% after 5 years. This in turn yields an excess risk of death or

Correspondence: Shoichi Takahashi, MD, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1–2–3, Kasumi, Minami-ku, Hiroshima, 734-8551 Japan. Tel: +81 82 257 5192. Fax: +81 82 257 5194. E-mail: shoichit@hiroshima-u.ac.jp

(Received 26 April 2010; accepted 26 June 2010)

ISSN 0036-5521 print/ISSN 1502-7708 online © 2010 Informa Healthcare
DOI: 10.3109/00365521.2010.505657



retransplantation for liver failure 10–15 years after transplantation [2]. Given this risk, it seems reasonable to offer antiviral therapy to liver transplant recipients. Many reports have noted rates of sustained viral response (SVR) ranging from only 10% to 30% in liver transplant recipients with recurrent HCV treated for 48 weeks [3–10], indicating the need for new treatment regimens with higher SVR rates. Recent reports have indicated that the extension of treatment with peginterferon and ribavirin (PEGIFN/RBV) from 48 to 72 weeks significantly increases the rate of SVR in immunocompetent patients, particularly slow virological responders [11,12], and one report noted that extended treatment for recurrent hepatitis C infection after liver transplantation (LT) was effective [13,14].

There are many predictive factors of successful treatment with the combination of peginterferon and ribavirin in immunocompetent patients, including the viral factors, such as HCV genotype, pretreatment viral load, amino acid (aa) 70 and/or 91 in the HCV core protein, amino acid substitutions in the HCV NS5A region [15–17]. In their multivariate analyses of predictors of SVR, Akuta and colleagues identified substitutions of aa 70 and 91 in the HCV core region (double-wild-type; odds ratio 5.988) as predictive [18], whereas Enomoto identified substitutions of amino acids of the HCV NS5A region (mutant type; odds ratio 5.3) as predictive [15].

With regard to length of treatment, one study reported that an early viral response at 3 months was useful in predicting a lack of response to antiviral therapy in liver transplant recipients with recurrent hepatitis C [19,20]. To our knowledge, however, no study has analyzed viral factors in extended treatment for recurrent hepatitis C infection after liver transplantation.

The aim of the present study was to evaluate the therapeutic efficacy of peginterferon in combination with ribavirin (PEGIFN/RBV) on long-term treatment for recurrent hepatitis C after LDLT, and predictive factors of virological response to this treatment, particularly viral factors. This study is first report of predictive factors associated with virological response in recurrent hepatitis C patients after LDLT, including amino acid substitutions in the core region and NS5A region.

Material and methods

Patients

A total of 53 patients who underwent LDLT due to HCV-related end-stage liver disease from 2000 to January 2009 were enrolled for this retrospective

study. Among them, 14 patients died before the start of therapy, 1 refused treatment with antiviral therapy, and 1 did not become positive for HCV RNA after LDLT. Eventually, leaving 37 patients treated with PEGIFN/RBV in our institution. Of these, 10 patients are currently continuing antiviral therapy.

We introduced all patients to IFN therapy in principle. The efficacy of IFN therapy could thus be established in 27 patients (Figure 1).

Antiviral treatment protocol

Patients received 1.5 µg/kg body weight (BW) PEGIFN (Peg-Intron; Schering-Plough, Segrate, Italy) subcutaneously (s.c.) once weekly and 200 mg RBV (Rebetol; Schering-Plough). PEGIFN/RBV was continued for more than 1 year after serum HCV RNA becomes negative. At the end of active treatment, the patients were followed for further 24 weeks without treatment.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Ethics Committees of all participating centers. Written informed consent was obtained from all participating patients.

Safety assessments

Safety was assessed by clinical and laboratory testing, and by evaluating all adverse events reported at each visit. In accordance with the protocol, growth factors were recommended to encourage optimum patient compliance in relation to predictable hematological side effects such as anemia.

Erythropoietin (EPO; Epogin, Chugai) from 6000 IU/week was used to treat anemia (Hb levels <10 g/dl). RBV was administered from 200 mg. When Hb increased by more than 10 g/dl, 200 mg per day of RBV was added. The daily dose of RBV was reduced by 200 mg when Hb fell below 10 g/dl, an acute decrease was followed by stabilization of Hb concentration at more than 3 g/dl from baseline, or the appearance of clinical symptoms of anemia (e.g. palpitation, dyspnea on effort, and fatigue) associated with a decrease in Hb of >2 g/dl from baseline. Once the RBV dose was reduced, it was maintained at that level throughout the rest of study if patients complained of anemia-related symptoms of fatigue or pallor. However, RBV was discontinued when Hb fell below 8.5 g/dl or when patients manifested more severe anemia, including orthostatic hypotension. PEGIFN was stopped if significant side effects occurred or if cytopenia persisted (neutrophil count <750/mm³, platelet count <20,000/mm³).




Figure 1. Flow diagram showing the course of HCV-infected patients after living donor liver transplantation. Twenty-seven patients treated with PEGIFN/RBV combination therapy were divided into two groups, namely sustained virological response (SVR) and non-SVR. *n*, number of patients. HCV genotype is shown.

Assessment of efficacy

HCV RNA levels were measured using one of several RT-PCR-based methods (original Amplicor method, high range method, or TaqMan RT-PCR test) at weeks 2 and 4, every 4 weeks of treatment thereafter, and at 24 weeks after the cessation of therapy.

The response was considered to be a SVR after another 6 months of negative serologic results without antiviral treatment. Patients with positive qualitative HCV RNA PCR tests during all examinations were categorized as having a non-virological response. Virological response (VR) was defined as becoming PCR-negative at least once during treatment; early virological response (EVR) as HCV-RNA-positive at 4 weeks after the start of treatment and HCV-RNA-negative at 12 weeks; and late virological response (LVR) as HCV-RNA-negative at more than 13 weeks after the start of treatment.

Analysis of nucleotide sequence of the core and NS5A region

Fifteen patients with genotype 1b completed our protocol. Seven patients achieved SVR whereas eight did not. Using serum obtained before LDLT, we analyzed amino acid (aa) substitutions at aa 70 and aa 91 of the HCV core region (HCV CR) and

mutation at the interferon sensitivity-determining region (ISDR) in the nonstructural 5A (NS5A) region of HCV by the direct sequencing method. The core aa 61–110 and NS5A aa 2209–2248 (IFN-sensitive determining region [ISDR]) [15] sequences were determined by direct sequencing using stored serum samples obtained just before therapy. HCV RNA was extracted from serum samples and reverse transcribed with random primers and MMLV reverse transcriptase (Takara Bio Inc., Shiga, Japan). DNA fragments were amplified by PCR using the primers below. Nucleotide sequences of the core region: first-round PCR was performed with primers CC11 (forward, 5'-GCC ATA GTG GTC TGC GGA AC-3') and e14 (reverse, 5'-GGA GCA GTC CTT CGT GAC ATG-3'), and second-round PCR with primers CC9 (forward, 5'-GCT AGC CGA GTA GTG TT-3') and e14 (reverse), as described by Akuta et al. [16,18,21]. After denaturation at 95°C for 5 min, 35 cycles of amplification were set as follows: denaturation for 30 s at 94°C, annealing of primers for 1.5 min at 57°C, and extension for 1 min at 72°C, followed by final extension at 72°C for 7 min. The second PCR was carried out with the same amplification conditions as those used in the first PCR, except that the second PCR primers were used instead of the first PCR primers. Nucleotide sequences of ISDR in NS5A: PCR was performed